{"id":530099,"date":"2021-02-12T21:50:02","date_gmt":"2021-02-12T21:50:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=530099"},"modified":"2021-02-12T21:50:02","modified_gmt":"2021-02-12T21:50:02","slug":"friedreichs-ataxia-market-analysis-leading-companies-emerging-drugs-and-epidemiology-forecast","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/friedreichs-ataxia-market-analysis-leading-companies-emerging-drugs-and-epidemiology-forecast_530099.html","title":{"rendered":"Friedreich’s Ataxia Market Analysis, Leading Companies, Emerging Drugs, and Epidemiology Forecast"},"content":{"rendered":"
\"Friedreich's<\/a><\/p>\n
\n
Delveinsight Business Research LLP<\/p>\n<\/div>\n<\/div>\n<\/div>\n
DelveInsight’s “Friedreich’s Ataxia Market Insights, Epidemiology, and Market Forecast 2030” report delivers an in-depth understanding of the Friedreich’s Ataxia, historical and forecasted epidemiology as well as the Friedreich’s Ataxia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/p>\n<\/div>\n

Friedreich’s Ataxia (FA)<\/strong> is a rare autosomal recessive neurodegenerative disease that causes progressive nervous system damage and movement problems. It usually begins in childhood and leads to impaired muscle coordination (ataxia) that worsens over time. Most patients carry homozygous GAA expansions in the first intron of the frataxin gene on chromosome 9. Frataxin is a mitochondrial protein. Due to epigenetic alterations, frataxin expression is reduced significantly, and its deficiency leads to mitochondrial iron overload, defective energy supply, and generation of reactive oxygen species.<\/p>\n

Get FREE sample copy at: 
<\/strong>https:\/\/www.delveinsight.com\/sample-request\/friedreichs-ataxia-market<\/a><\/strong><\/p>\n

The Friedreich’s Ataxia market report also covers emerging drugs, current treatment practices, Friedreich’s Ataxia market share<\/strong> of the individual therapies, current and forecasted Friedreich’s Ataxia Market Size from 2017 to 2030 segmented by seven major markets. <\/p>\n

The report provides a detailed current Friedreich’s Ataxia treatment practice\/algorithm<\/strong>, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market. <\/p>\n

\"Friedreich's<\/p>\n

Friedreich’s Ataxia Market Key Facts<\/strong><\/p>\n

According to the literature survey, both male and female children can inherit this disorder. There is no gender difference in the prevalence of this neurodegenerative disorder.<\/p>\n

Various Epidemiological studies provide evidence of a west to east prevalence gradient in Europe with the highest levels in the South of France, North of Spain, and Ireland and lowest levels in Scandinavia and Russia (Katrin et al.).<\/p>\n

As per the statistics by the National Institute of Neurological Disorders and Stroke, although rare, FA is the most common form of hereditary ataxia in the United States, affecting about 1 in every 50,000 people. Adult or late-onset FA is less common, <25% of diagnosed individuals, and can occur anytime during adulthood.<\/p>\n

Key Benefits of Friedreich’s Ataxia Market Report<\/strong><\/p>\n